Sara Nik
Stock Analyst at H.C. Wainwright
(0.05)
# 4,793
Out of 5,076 analysts
60
Total ratings
10.9%
Success rate
-32.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiated Coverage: Buy | $23 | $7.26 | +216.80% | 1 | Oct 16, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.4049 | +640.92% | 12 | Oct 5, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $60 | $6.50 | +823.08% | 20 | Sep 29, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 12.00 | kr 1.38 | +767.05% | 11 | Sep 21, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $9 | $0.94 | +857.45% | 5 | Aug 21, 2026 | |
| CRIS Curis | Reiterated: Buy | $43 | $0.3863 | +11,031.25% | 10 | Aug 17, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.5585 | n/a | 1 | Aug 13, 2025 |
Eikon Therapeutics
Oct 16, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $7.26
Upside: +216.80%
Pasithea Therapeutics
Oct 5, 2026
Reiterated: Buy
Price Target: $3
Current: $0.4049
Upside: +640.92%
Moleculin Biotech
Sep 29, 2026
Reiterated: Buy
Price Target: $60
Current: $6.50
Upside: +823.08%
Cantargia AB (publ)
Sep 21, 2026
Reiterated: Buy
Price Target: kr 12.00
Current: kr 1.38
Upside: +767.05%
Tvardi Therapeutics
Aug 21, 2026
Reiterated: Buy
Price Target: $9
Current: $0.94
Upside: +857.45%
Curis
Aug 17, 2026
Reiterated: Buy
Price Target: $43
Current: $0.3863
Upside: +11,031.25%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.5585
Upside: n/a